INT J LAB HEMATOL:评价四种新型凝血法测定纤维蛋白原、D二聚体和凝血酶时间的分析性能

2019-01-31 MedSci MedSci原创

测量止血功能新的实验室方法需要在常规使用前进行仔细评估。本研究通过Clauss法、凝血酶原时间衍生的凝血酶原、凝血酶时间和D二聚体水平评价了四种新的凝血法测定纤维蛋白原的分析性能。研究人员采用欧洲4个中心的cobas t 711和cobas t 511分析仪对4种检测方法进行评价。根据临床和实验室标准协会指南(EP09 A3, EP05 A3),使用匿名柠檬酸钠(3.2% [0.109M])血浆样

测量止血功能新的实验室方法需要在常规使用前进行仔细评估。本研究通过Clauss法、凝血酶原时间衍生的凝血酶原、凝血酶时间和D二聚体水平评价了四种新的凝血法测定纤维蛋白原的分析性能。研究人员采用欧洲4个中心的cobas t 711cobas t 511分析仪对4种检测方法进行评价。根据临床和实验室标准协会指南(EP09 A3, EP05 A3),使用匿名柠檬酸钠(3.2% [0.109M])血浆样本,进行分析性能和方法与其他市售分析方法的比较。对cobas t711cobas t511分析仪的批间可变性和每种分析的等效性也进行了评估。

结果显示,总体上,运行精度范围内的变异系数为4.1%,总重现性范围内的变异系数为8.6%。方法对比实验表明,与各自的comparator方法相比,每种分析方法的一致性较好或可接受,两种cobas t平台具有相当的一致性(Pearson相关系数0.991)。所有四种分析的lot之间均观察到高水平的一致性(Pearson相关系数0.994)

研究部门,本次多中心研究在cobast711cobast511分析仪上对四种新的凝血试验结果进行了较好的分析。

原始出处:

Steve Kitchen Ulrich Geisen Janos Kappelmayer, Evaluating the analytical performance of four new coagulation assays for the measurement of fibrinogen, Ddimer and thrombin time

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950371, encodeId=0ed419503e172, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662282, encodeId=a3c8166228241, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 23 05:33:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997268, encodeId=c62c199e26854, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 06 03:33:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317471, encodeId=54eb131e4716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362612, encodeId=98461362612d0, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444494, encodeId=66dd1444494d9, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-12-26 hxj0117
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950371, encodeId=0ed419503e172, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662282, encodeId=a3c8166228241, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 23 05:33:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997268, encodeId=c62c199e26854, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 06 03:33:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317471, encodeId=54eb131e4716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362612, encodeId=98461362612d0, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444494, encodeId=66dd1444494d9, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950371, encodeId=0ed419503e172, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662282, encodeId=a3c8166228241, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 23 05:33:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997268, encodeId=c62c199e26854, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 06 03:33:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317471, encodeId=54eb131e4716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362612, encodeId=98461362612d0, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444494, encodeId=66dd1444494d9, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1950371, encodeId=0ed419503e172, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662282, encodeId=a3c8166228241, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 23 05:33:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997268, encodeId=c62c199e26854, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 06 03:33:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317471, encodeId=54eb131e4716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362612, encodeId=98461362612d0, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444494, encodeId=66dd1444494d9, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-02 fengyi812
  5. [GetPortalCommentsPageByObjectIdResponse(id=1950371, encodeId=0ed419503e172, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662282, encodeId=a3c8166228241, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 23 05:33:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997268, encodeId=c62c199e26854, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 06 03:33:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317471, encodeId=54eb131e4716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362612, encodeId=98461362612d0, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444494, encodeId=66dd1444494d9, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1950371, encodeId=0ed419503e172, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Dec 26 00:33:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662282, encodeId=a3c8166228241, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 23 05:33:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997268, encodeId=c62c199e26854, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 06 03:33:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317471, encodeId=54eb131e4716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362612, encodeId=98461362612d0, content=<a href='/topic/show?id=9f6ce72774d' target=_blank style='color:#2F92EE;'>#纤维蛋白原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77277, encryptionId=9f6ce72774d, topicName=纤维蛋白原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444494, encodeId=66dd1444494d9, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Feb 02 14:33:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-02 huagfeg

相关资讯

Ophthalmologica:视网膜脱离患者的玻璃体视网膜下液体中凝血酶的生成

荷兰鹿特丹眼科医院的Mulder VC近日在Ophthalmologica发表了一篇文章,他们测量了孔源性视网膜脱离(RRD)患者的玻璃体和视网膜下部液体(SRF)中凝血酶原片段(F1 + 2)和凝血酶-抗凝血酶复合物(TAT)的活性,并进一步证实了他们较早之前发现的增生性玻璃体视网膜病变(PVR)患者中凝血酶活性上升。

异常凝血酶原检测超早期发现HBV感染者肝细胞癌1例

患者男性,53岁,2016年6月18日因“腹泻半月”入院。

JCLA:Clauss和凝血酶原时分方法联合使用以确定纤维蛋白原浓度:筛查先天性不良纤维蛋白原血症

在这项研究中,研究了通过clauss和凝血酶时分筛查先天性异常纤维蛋白原血症的方法的组合评估的纤维蛋白原浓度的重要性,并分析了纤维蛋白原PT衍生/ Clauss比率对先天性异常纤维蛋白原血症的筛选效率。 我们在73例先天性异常纤维蛋白原血症患者和81例正常对照中比较了通过Clauss,PT-和酶联免疫吸附试验(ELISA)方法确定的纤维蛋白原浓度。使用ROC曲线来评估纤维蛋白原PT衍生/Clau

J Thromb Haemost:瑞舒伐他汀可减少静脉血栓栓塞患者的凝血酶生成

他汀疗法是静脉血栓栓塞(VTE)的一种替代预防治疗方法,因为他汀被证明可以下调止血功能并预防VTE再发,而不增加出血风险。2018年12月,发表在《J Thromb Haemost.》的一项随机对照研究调查了,他汀是否影响既往VTE患者的凝血功能。

IGLH:在餐后脂肪血症期间,VIIaAT复合物、促凝磷脂、凝血酶的产生如何?

活化因子VII在餐后发生激活。部分活化因子VII (VIIa)与抗凝血酶(VIIaAT)形成复合物在体内循环。本研究的主要目是评估餐后脂肪血症对循环的VIIaAT、促凝磷脂(PPL)活性和凝血酶产生的影响。 在标准化口服脂肪耐受性试验(OFTT)中,分别从从后心肌梗死患者(n = 40)和对照组(n = 39)在服药前以及在测试第3和第6小时采集血浆样本。在第2组108例梗死后患者和109例

IGLH:高发病率的凝血酶的产生和/或减少血小板反应的妇女有不明原因的月经出血

严重的月经出血(HMB)影响到了20% - 30%的育龄妇女。HMB有一个多因素病理生理学现象,目前对其仍不完全了解。HMB的症状在止血缺陷患者中很常见,同样,月经期大出血的女性,其受损的Von Willebrand因子(VWF)水平和功能、血小板减少、血小板功能受损和凝血功能受损的发生率均较高。本研究的目的是量化在HMB患者中血小板功能受损、凝血功能减弱和VWF活性降低的情况。 研究人员使